The aim of the PRECISE biobank is to develop the first, smart multi-modal liquid biopsy test service for the prediction of immune checkpoint inhibitor response in urothelial cancer (UC) patients – the PRECISE IVD. The biobank contains biomaterial (PBMCs, cfDNA and PAXgene) and clinical data from patients with metastatic UC in whom treatment with anti-PD-(L)1 has been initiated.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Farewell Dorine Swinkels
1 September 2026On Friday, September 4th, 2026, Dorine Swinkels will retire as Professor of Experimental Clinical Chemistry at Radboudumc. She is also leaving the Radboud Biobank.
go to page
Greening Radboud Biobank – reduction number of aliquots in storage for future initiatives
1 September 2026Like LUMC and NKI, the Radboud Biobank will also store fewer aliquots per collection tube.
go to page
Effect of Fit & Funding on external invoices
1 September 2026The Radboud Biobank not only manages issuances and projects for Radboudumc but also provides external services. The Radboud Biobank invoices the external organization for these services.
go to page
New link between iLES and Castor EDC connects clinical data and biobank material
1 September 2026The Biobank Information Management System, iLES, is now linked to Castor EDC. This development was realized within a KWF-funded project.
go to page
Radboud Biobank's 2025 annual report
3 March 2026The Radboud Biobank's 2025 annual report is now available on request.
go to page
Aevai Health developed a virtual assistant
3 March 2026Aevai Health has developed Alva - a virtual assistant to engage research participants, which can support participants with health literacy, understanding research protocols, and with using measurement devices.
go to page